Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.

Presentation Details:

Date: April 3, 2023Time: 1:00 – 1:30 pm Location: Jefferies Conference Center, NYC, New York

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc. Investor RelationsKim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com

Follow Monopar on social media for updates:  Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Sep 2023 to Oct 2023 Click Here for more Monopar Therapeutics Charts.
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Oct 2022 to Oct 2023 Click Here for more Monopar Therapeutics Charts.